Osimertinib-Resistant Cell Lines and Models
Despite the robust clinical activity exerted by osimertinib, a majority of patients eventually exhibit disease progression while receiving this drug. Resistance to osimertinib includes both on-target and off-target mechanisms. With the use of osimertinib for advanced EGFR-mutant NSCLC increasing, the development of targeted therapies toward osimertinib resistance represents an unmet medical need. To support research in this area, WuXi AppTec offers an extensive panel of validated, osimertinib-resistant cell lines and in vivo models.
Check out our comprehensive platform of drug-resistant models by clicking HERE.
Genetically engineered Osimertinib-resistant cell lines and models
Related Content
Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug,...
VIEW RESOURCEWith advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets, often referred...
VIEW RESOURCE